

Article

Synthesis and Properties of α -Mangostin and Vadimezan Conjugates with Glucoheptoamidated and Biotinylated 3rd Generation Poly(amidoamine) Dendrimer, and Conjugation Effect on Their Anticancer and Anti-Nematode Activities

Joanna Markowicz ^{1,*} , Stanisław Wołowicz ² , Wojciech Rode ³  and Łukasz Uram ¹ 

¹ Faculty of Chemistry, Rzeszów University of Technology, 6 Powstanców Warszawy Ave, 35-959 Rzeszów, Poland; l.urang@prz.edu.pl

² Medical College, Rzeszów University, 1a Warzywna Str., 35-310 Rzeszów, Poland; swolowicz@ur.edu.pl

³ Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093 Warsaw, Poland; w.ode@nencki.edu.pl

* Correspondence: jmarkowicz@stud.prz.edu.pl



Citation: Markowicz, J.; Wołowicz, S.; Rode, W.; Uram, Ł. Synthesis and Properties of α -Mangostin and Vadimezan Conjugates with Glucoheptoamidated and Biotinylated 3rd Generation Poly(amidoamine) Dendrimer, and Conjugation Effect on Their Anticancer and Anti-Nematode Activities. *Pharmaceutics* **2022**, *14*, 606. <https://doi.org/10.3390/pharmaceutics14030606>

Academic Editors: Kristiina Huttunen and Magdalena Markowicz-Piasecka

Received: 8 February 2022

Accepted: 7 March 2022

Published: 10 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: α -Mangostin and vadimezan are widely studied potential anticancer agents. Their biological activities may be improved by covalent bonding by amide or ester bonds with the third generation poly(amidoamine) (PAMAM) dendrimer, substituted with α -D-glucoheptono-1,4-lactone and biotin. Thus, conjugates of either ester- ($G3^{8h4B5V}$) or amide-linked ($G3^{2B12gh5V}$) vadimezan, and equivalents of α -mangostin ($G3^{8h2B5M}$ and $G3^{2B12gh5M}$, respectively), were synthesized, characterized and tested in vitro against cancer cells: U-118 MG glioma, SCC-15 squamous carcinoma, and BJ normal human fibroblasts growth, as well as against *C. elegans* development. α -Mangostin cytotoxicity, stronger than that of Vadimezan, was increased (by 2.5–9-fold) by conjugation with the PAMAM dendrimer (with the amide-linking being slightly more effective), and the strongest effect was observed with SCC-15 cells. Similar enhancement of toxicity resulting from the drug conjugation was observed with *C. elegans*. Vadimezan (up to 200 μ M), as well as both its dendrimer conjugates, was not toxic against both the studied cells and nematodes. It showed an antiproliferative effect against cancer cells at concentrations ≥ 100 μ M. This effect was significantly enhanced after conjugation of the drug with the dendrimer via the amide, but not the ester bond, with $G3^{2B12gh5V}$ inhibiting the proliferation of SCC-15 and U-118 MG cells at concentrations ≥ 4 and ≥ 12 μ M, respectively, without a visible effect in normal BJ cells. Thus, the drug delivery system based on the PAMAM G3 dendrimer containing amide bonds, partially-blocked amino groups on the surface, larger particle diameter and higher zeta potential can be a useful tool to improve the biological properties of transported drug molecules.

Keywords: α -mangostin conjugate; vadimezan conjugate; PAMAM G3 dendrimer; cytotoxicity; proliferation; glioblastoma; squamous cell carcinoma; human fibroblasts; *Caenorhabditis elegans*

1. Introduction

Many natural and synthetic compounds with anticancer potential are not active enough in terms of bioavailability and full exploitation of their biological properties. Xanthones, presenting examples of such compounds, are polyphenolic heterocyclic compounds that can be isolated from mangosteen rind or semi/fully synthesized [1]. α -Mangostin (α M), the main representative of the xanthones family, exhibits anticancer activity through various molecular mechanisms, the most important of which are the induction of mitochondria-mediated apoptosis and the inhibition of proliferation, migration, invasion, and angiogenesis [2–6]. These activities were confirmed with in vitro and in vivo models of brain [7], pancreatic [8], liver [9], cervical [10], prostate [11] and colorectal [12] cancers. Recently, α M co-administered with doxorubicin was reported to be effective in reducing cell stemness in luminal breast cancer [13].

Another xanthone, vadimezan (5,6-dimethylxanthenone-4-acetic acid, DMXAA, ASA404), is an analogue of flavone acetic acid, considered one of the most promising antivascular agents. Direct and indirect mechanisms of action have been proposed for Vadimezan (V). A direct mechanism of V action includes the induction of apoptosis in endothelial cells, which causes hemorrhagic necrosis and ischemia in tumor tissues and, consequently, a specific and irreversible destruction of established tumor vasculatures, resulting in the complete blockade of tumor blood flow. Indirect mechanisms of V action include activation of the innate immune system, which stimulates production of inflammatory cytokines (such as TNF and IL-6), activation of NF κ B and p38 (MAPK), production of nitric oxide, and reduction of tumor energetics and membrane turnover [14,15]. Later, the molecular target of V was discovered—the stimulator-of-interferon-genes (STING) protein that plays a central role in the innate immune system response. Although due to the satisfying results of in vivo studies, V has undergone several clinical trials as a single agent or in combination with taxanes, as well as in the context of carboplatin-based chemotherapy, the results of phase III clinical trials were disappointing [16]. One of the reasons for the lack of efficacy is the specificity of V to stimulate only murine STING protein but not the human STING [17]. Despite the failure of V to act as a STING agonist, attempts are made to re-develop V alone or in combination with properly targeted delivery systems. Liu et al. [18] introduced the hSTING mutant, STING^{S162A/G230I/Q266I}, to reignite STING activity in Merkel cell carcinoma (MCC), where it is completely silenced. Since this hSTING mutant is highly sensitive to V, the delivery of STING^{S162A/G230I/Q266I} to MCC cells and treatment with V stimulated downstream antitumor cytokine production, T cell migration, and T cell activation in vitro. Boron difluoride dipyrromethene (BODIPY)-vadimezan conjugate was synthesized and enwrapped in mPEG-PPDA polymer brushes to obtain a highly-efficient type I photosensitizer for photodynamic therapy of hypoxic-and-metastatic tumors [19].

The employment of drug nanocarriers can improve water solubility and biodistribution of a drug transported in an organism. An ideal nanocarrier should present certain features, among which the most important are hydrophilicity, biocompatibility, and non-immunogenicity. Furthermore, it should be easy to conjugate or encapsulate the transported drug, as well as a proper ligand or targeting moiety, which can direct the drug to selected tissues and cells compartments [20]. Poly(amidoamine) (PAMAM) dendrimers meet the above-mentioned requirements. They are three-dimensional and hyperbranched polymers, attractive for drug delivery purposes [21,22]. Due to their spherical shape and easy-to-modify surface amine groups, they allow for the sustained release of the drug. This effect can be achieved by selecting an appropriate linkage between drug and nanocarrier. The use of different types of drug linkages can result in different drug release sites and rates. The mechanism of drug release may involve enzymatic or pH-dependent hydrolysis. Amide and ester bonds are most commonly used for the conjugation of small drugs to polymers, whereas other linkages, for example, disulfide bonds, have also been demonstrated. Amide bonds are generally stable towards various reaction conditions (acidic and basic), high temperature, and the presence of other chemicals. Additionally, they are the least reactive and their degradation is very slow as the amide bond is stabilized by the partial double bond [23]. However, Luo et al. [24] proved that in a multifunctional enveloped nanocarrier with PEG-PLL(DMA) (poly(ethylene glycol)-blocked-2,3-dimethylmaleic anhydride-modified poly(L-lysine) on its surface, the hydrolysis of amide linkages between amines and DMA occurred at acidic pH, while at physiological pH, amide bonds remained stable. The main enzymes responsible for amide hydrolysis are serine and cysteine hydrolases [25]. Ester linkages are generally easy to hydrolyze and the esterases play a major role in their enzymatic degradation. Furthermore, esterase hydrolysis represents an interesting potential strategy for targeted therapy of cancers that overexpress esterases, or which express esterases with different specificities [26,27]. Kurtoglu et al. compared ibuprofen release profiles from ester- and amide-bonded conjugates of the PAMAM G4 dendrimer and found

that while the hydrolysis of ester bonds was pH-dependent, the amide conjugates were very stable at all pH buffers, suggesting the drug release to be caused by enzymatic cleavage [28].

We have previously used biotinylated and glucoheptoamidated 3rd generation poly(ami doamine) dendrimer (PAMAM G3) to covalently attach α M by amide bond ($G3^{12gh2B5M}$) [29] and demonstrated that drug coupling with the non-toxic vehicle significantly increased its cytotoxicity and improved other biological activities, such as pro-apoptotic and anti-proliferative in vitro, as well as nematocidal in vivo. The goal of this paper was the design, synthesis and characterization of three biotinylated and glucoheptoamidated PAMAM G3 dendrimer conjugates: (i) with ester-linked α M ($G3^{gh2B5M}$), (ii) with ester-linked V ($G3^{gh4B5V}$) and (iii) with amide-linked V ($G3^{12gh2B5V}$) and investigation of the influence of their size, zeta potential, and the type of chemical bond between drugs and carrier on their biological activity in vivo and in vitro. Biotin was used as a targeting agent, in view of certain cancer cells having been demonstrated to overexpress biotin receptors and transporters [30]. Moreover, biotinylation of PAMAM dendrimers significantly increases cellular uptake and accumulation of these nanoparticles compared to non-biotinylated ones [31–34]. Biotinylation allows also PAMAM dendrimers to cross the blood-brain barrier more effectively, which is essential in the treatment of central nervous system tumors, for example, gliomas [35]. Glucoheptoamidation was performed to increase the conjugate solubility and block the amine groups present on the dendrimer surface that are responsible for the cytotoxicity of the native PAMAM G3 dendrimers [36]. The NMR and DLS analyses of the obtained conjugates were performed. The anti-cancer activity of conjugates was studied on human grade IV glioma cells (U-118 MG), human squamous carcinoma cells (SCC-15), compared to normal human fibroblasts (BJ). *Caenorhabditis elegans* nematode, widely used in nano-sciences to study genotoxicity, neurotoxicity and impact on reproduction [37], was used to study nematocidal activity in vivo.

2. Materials and Methods

2.1. Reagents

α -Mangostin (α M, purity $\geq 98\%$ (HPLC)) was purchased from Aktin Chemicals, Inc. (Chengdu, China) and vadimezan (V, DMXAA, purity $> 98\%$) was obtained from DC Chemicals (Shanghai, China). Ethylenediamine, methyl acrylate, D-glucoheptono-1,4-lactone (GHL), succinic anhydride (SucAnh), 2-chloro-1-methylpyridinium iodide (Mukaiyama reagent), 4-dimethylaminopyridine (DMAP), biotin, dimethyl sulfoxide (DMSO) and other reagents used in chemical syntheses were provided by Merck KGaA (Darmstadt, Germany). Spectra/Por® 3 RC dialysis membrane (cellulose, MW_{cutoff} = 3.5 kDa) was purchased in Carl Roth GmbH & Co. KG (Karlsruhe, Germany).


2.2. Biochemical Reagents, Cell Lines and Materials

Human cancer cell lines: glioblastoma (U-118 MG) and squamous cell carcinoma (SCC-15), human normal fibroblast cell line (BJ), Eagle's Minimum Essential Medium (EMEM) and fetal bovine serum (FBS) used for supplementation of this medium were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Dulbecco's Modified Eagle's Media (DMEM and DMEM/F-12) and fetal bovine serum (FBS) were purchased from Corning Inc. (New York, NY, USA). Penicillin and streptomycin solution, phosphate-buffered saline (PBS) with and without magnesium and calcium ions, and Hoechst 33,342 were provided by Thermo Fisher Scientific Inc. (Waltham, MA, USA). Trypsin-EDTA solution, hydrocortisone, 0.33% neutral red solution, XTT sodium salt, phenazinemethosulfate (PMS), 0.4% trypan blue solution, dimethylsulfoxide (DMSO) for molecular biology, 5-Fluoro-2'-deoxy-uridine (FUdR), and other chemicals and buffers were purchased from Merck KGaA (Darmstadt, Germany). Cell culture dishes and materials were from Corning Inc. (New York, NY, USA), Greiner (Kremsmünster, Austria), or Nunc (Roskilde, Denmark). All reagents used to culture and synchronize *C. elegans* nematodes were supplied by Sigma-Aldrich (Saint Louis, MO, USA) or Carl Roth GmbH & Co. KG (Karlsruhe, Germany).

2.3. Syntheses of Dendrimer Conjugates with Ester-Bonded Biotin and α -Mangostin or Vadimezan

2.3.1. Synthesis of Fully Glucoheptoamidated PAMAM G3

PAMAM G3 dendrimer was obtained according to Tomalia's protocol [38] and was converted into fully glucoheptoamidated derivative $G3^{gh}$ by reaction with an excess of α -D-glucoheptono-1,4-lactone (GHL) in DMSO (Scheme 1A) as described earlier [39] on a scale of 95 μ moles. Thus, the PAMAM G3 (661 mg, 95.6 μ moles) was dissolved in 5 mL of DMSO. To this solution a two-fold excess of GHL (1273 mg, 6118 μ moles) was added in portions with vigorous stirring. The mixture was heated at 50 °C for 12 h, transferred to a dialytic bag and dialyzed for 3 days against water. Water was removed by vacuum rotary evaporation and a solid residue was dried overnight under high vacuum (2 mbars). The final product ($G3^{gh}$) was obtained in 35.4% yield (459 mg, 33.83 μ moles, MW = 13,568 g mol⁻¹). This compound was then used as a core dendrimer to attach covalently biotin and α -mangostin or vadimezan via ester bonds. Five μ moles of $G3^{gh}$ were used as stock solution (12.7 mM in water) for biological studies to evaluate the cytotoxicity of the dendrimeric nanocarrier.



Scheme 1. The conversion of (A) PAMAM G3 dendrimer into fully glucoheptoamidated derivative $G3^{gh}$ and (B) α -mangostin into carboxy-terminated derivative α M-Suc using succinic anhydride.

2.3.2. Synthesis of Biotinylated $G3^{gh}$ — α -Mangostin Conjugate


The α -mangostin (α M) was converted into a 6-succinate derivative with succinic anhydride (Scheme 1B) as it was performed previously [39].

46.3 mg (112 μ moles) of α M was dissolved in 2 mL of DMSO and then succinic anhydride (17 mg, 168 μ moles) was added. The solution was heated at 60 °C for 2 h and used later to conjugate α M to dendrimer as follows: to the $G3^{gh}$ dendrimer (300 mg, 22 μ moles) solution in 2 mL of DMSO, 11 mg of biotin (44 μ moles) was added followed by dropwise addition of α M-Suc in DMSO. Then, DMAP (57.2 mg, 468 μ moles) and Mukaiyama reagent (59.8 mg, 234 μ moles) were added and the mixture was heated at 50 °C for 18 h. Afterwards, the solution was transferred into a dialytic tube (cellulose, MW_{cutoff} = 3.5 kDa) and dialyzed for 3 days against water (six times 3 L). Water was removed by rotary evaporation and remained solid was dried under high vacuum for 12 h. 201 mg of final product was obtained and dissolved in 2.5 mL of DMSO-d₆. The product was identified by ¹H-NMR spectroscopy as $G3^{gh}2B5M$ and stored as a stock solution of 4.9 mM concentration. The isolated yield of the product was 55.5% (12.2 μ moles, MW_{calc} = 16,451 g mol⁻¹).

Analytical data:

¹H NMR (DMSO-d₆): chemical shift [ppm] (intensity, multiplicity, assignment): $G3^{gh}2B5M$ (for atom numbering see Scheme 2, for spectrum see Figure 1B): 13.73 ([5H], s,

1^M); 6.79 ([5H], s, 5^M); 6.34 ([5H], s, 4^M); 5.15 ([10H], overlapped t, 12^M , 17^M); 3.99 ([10H], m, 11^M); 3.69 ([15H], s, 7^M); 3.19 ([10H], 16^M); 1.69 ([60H], overlapped s, 14^M , 15^M , 19^M , 20^M); PAMAM G3 resonances: 7.93 ([60+32H], m, NH(G3)); 3.13–2.20 ([484H], $\text{CH}_2(\text{G3})$); biotin resonances: 6.48 and 6.40 ([4H], s and s, 10^B and 11^B); 4.29 and 4.12 ([4H], s and s, 8^B and 9^B); glucoheptoamide OH resonances: 5.62, 5.07–4.16 (overlapped s, OH^{gh}); CH_2 resonances: 3.94 ([32H], bm, 2^{gh}); 3.86 ([32H], bm, 4^{gh}); 3.69 (m, 3^{gh} overlapped with 7^M); 3.60–3.30 ([128H], overlapped s and m, $5\text{--}7^{gh}$). For detailed peak assignments see COSY spectrum (Figure S1, Supplementary materials), HSQC/HMBC combined spectra (Figure S2), and Table S1.



Scheme 2. Synthesis of PAMAM G3^{gh} dendrimer conjugates with α -mangostin (1) or vadimezan (2), and biotin attached via ester bond: (1) **G3^{gh}2B5M** ($a_1 = 5$, $a_2 = 0$, $b = 2$, $c = 25$), (2) **G3^{gh}4B5V** ($a_1 = 0$, $a_2 = 5$, $b = 4$, $c = 23$).

2.3.3. Synthesis of Biotinylated G3^{gh}—Vadimezan Conjugate

The **G3^{gh}** dendrimer (172 mg, 12.7 μmoles) was dissolved in 3 mL of DMSO. In this solution, vadimezan (20.0 mg, 76 μmoles) and biotin (18.6 mg, 76 μmoles) were dissolved. Then DMAP (74.4 mg, 608 μmoles) was added followed by stepwise addition of Mukaiyama reagent (77.8 mg, 304 μmoles) into solution and heated at 50 °C for 18 h. The mixture was placed in a dialytic bag (cellulose, $\text{MW}_{\text{cutoff}} = 3.5 \text{ kDa}$) and dialyzed against water

for 4 days (8 times 3L). Water was evaporated at 50 °C and remaining solid (71 mg) was dissolved in 650 µL DMSO- d_6 . The ^1H NMR spectrum was taken at room temperature and the average stoichiometry of conjugate was determined based on integral integration of biotin (B) and vadimezan (V) resonances versus G3^{gh} reference resonances (vide infra), as $\text{G3}^{\text{gh4B5V}}$. The concentration of $\text{G3}^{\text{gh4B5V}}$ in DMSO- d_6 was 6.9 mM. The isolated yield of the product was 35% (71 mg, 4.5 µmoles, $\text{MW}_{\text{calc}} = 15,795 \text{ g mol}^{-1}$).

Analytical data:

^1H NMR (DMSO- d_6): chemical shift [ppm] (intensity, multiplicity, assignment): $\text{G3}^{\text{gh4B5V}}$ (for atom numbering see Scheme 2, for spectrum see Figure 2B): 8.20–7.72 ([75H], m, $\text{NH}(\text{G3})+1,8,3^{\text{V}}$); 7.38 and 7.26 ([10H], overlapped t and d, 2^{V} and 7^{V}); 2.37 ([30H], overlapped, $14^{\text{V}}, 15^{\text{V}}$); biotin resonances: 6.46 and 6.40 ([4H] and [4H], overlapped s, 10^{B} and 11^{B}); 4.31 and 4.13 ([4H] and [4H], 8^{B} and 9^{B}); 2.82 and 2.78 ([4H] and [4H], 6^{B} and 7^{B}); 2.05 ([8H], 2^{B}); 1.56–1.29 ([24H], overlapped m, $3^{\text{B}}, 4^{\text{B}}, 5^{\text{B}}$); gh OH resonances: 5.60 ([32H], s, $2'^{\text{gh}}$); 4.86 ([32H], s, $3'^{\text{gh}}$); 4.54–4.43 ([128H], m, $4'-7'^{\text{gh}}$); gh CH_2 resonances: 3.94 ([32H], bs, 2^{gh}); 3.85 ([32H], bs, 4^{gh}); 3.69 ([32H], bs, 3^{gh}); 3.58–3.43 ([128H], m, $5^{\text{gh}}, 6^{\text{gh}}, 7^{\text{gh}}$); PAMAM G3 CH_2 broad resonances: 3.13–2.19 ([484H], $\text{CH}_2(\text{G3})$).

For detailed peak assignments see COSY spectrum (Figure S3), HSQC/HMBC combined spectra (Figure S4), and Table S1. For comparison the vadimezan spectrum (Figure 2A) was recorded and the resonances were assigned based on 2-D COSY and HSQC/HMBC spectra: 8.09 ([1H], d, 1^{V}); 7.92 ([1H], d, 8^{V}); 7.79 ([1H], d, 3^{V}); 7.41 ([1H], t, 2^{V}); 7.30 ([1H], d, 7^{V}); 3.98 ([2H], s, 16^{V}); 2.41 ([6H], overlapped s, $14, 15^{\text{V}}$).

2.4. Syntheses of Dendrimer Conjugates with Amide-Bonded Biotin, GHL and α -Mangostin or Vadimezan


The detailed synthetic pathway of biotinylated and half-glucoheptoamidated dendrimer PAMAM G3 with α -mangostin ($\text{G3}^{2\text{B12gh5M}}$) and its chemical characterization were described previously [29].

Synthesis of Biotinylated and Half-Glucoheptoamidated G3 with Vadimezan

Vadimezan (53 mg, 188 µmoles) and biotin (23 mg, 94 µmoles) were dissolved in 4 mL of DMSO. To this solution 51.7 mg (423 µmoles) of DMAP and 72 mg (282 µmoles) of Mukaiyama reagent were added, stirred until completely dissolved, and left at room temperature for 1 h. This mixture was added dropwise to a PAMAM G3 dendrimer (216 mg, 31.3 µmoles) solution in 2 mL of DMSO, followed by heating at 50 °C for 18 h. The reaction mixture was worked-up by dialysis, evaporation of solvent, and drying under high vacuum as before. The obtained solid was slightly soluble in DMSO. The ^1H -NMR analysis allowed us to identify the product as $\text{G3}^{2\text{B5V}}$ and the isolated yield was 35.5% (87 mg, 11.1 µmoles, $\text{MW}_{\text{calc}} = 7810 \text{ g mol}^{-1}$). Finally, glucoheptoamidation of the remaining amine groups was performed by reaction of $\text{G3}^{2\text{B5V}}$ with GHL (Scheme 3). Thus, to $\text{G3}^{2\text{B5V}}$ solution (87 mg, 11.1 µmoles) in 2.25 mL of DMSO- d_6 , GHL (28 mg, 133.6 µmoles) was added stepwise with vigorous stirring at RT. The product became soluble in DMSO. The ^1H -NMR measurement was performed and allowed the determination of average stoichiometry of the conjugate as $\text{G3}^{2\text{B12gh5V}}$. Based on a calculated average molecular weight ($\text{MW}_{\text{calc}} = 11,306 \text{ g mol}^{-1}$) the stock solution of this conjugate was estimated as 3.3 mM.

Analytical data:

^1H NMR (DMSO- d_6): chemical shift [ppm] (intensity, multiplicity, assignment): $\text{G3}^{2\text{B12gh5V}}$ (for atom numbering see Scheme 3, for spectrum see Figure 2C): 8.20–7.69 ([73H], m, $\text{NH}(\text{G3})+1,8,3^{\text{V}}$); 7.33 ([10H], overlapped t and d, 2^{V} and 7^{V}); biotin resonances: 6.46 and 6.40 ([2H] and [2H], overlapped s, 10^{B} and 11^{B}); 2.05 ([4H], 2^{B}); 1.61–1.29 ([12H], $3^{\text{B}}, 4^{\text{B}}, 5^{\text{B}}$); gh OH resonances: 4.43–4.28 ([36H], m, $2'-4'^{\text{gh}}$); gh CH_2 resonances: 3.87–3.71 ([36H], m, $2-4^{\text{gh}}$); 3.58–3.37 ([48H], m, $5-7^{\text{gh}}$); PAMAM G3 CH_2 broad resonances: 3.09–2.20 ([484H], $\text{CH}_2(\text{G3})$).



Scheme 3. Synthesis pathway of PAMAM G3 dendrimer substituted with vadimezan, biotin and α -D-glucosylheptono-1,4-lactone attached via amide bond: $G3^{2B12gh5V}$ ($a = 5$, $b = 2$, $c = 13$, $d = 12$).

2.5. NMR Spectroscopy

The 1-D 1H and ^{13}C NMR spectra and 2-D 1H - 1H correlations spectroscopy (COSY), 1H - ^{13}C heteronuclear single quantum correlation (HSQC), and heteronuclear multiple bond correlation (HMBC) spectra were obtained with Bruker 300 MHz instrument (Rheinstetten, Germany) at the University of Rzeszow (College of Natural Sciences).

2.6. Conjugates Size and ζ Potential Measurements

ζ potential and size of $G3^{gh2B5M}$, $G3^{12gh2B5M}$, $G3^{gh4B5V}$ and $G3^{12gh2B5V}$ were estimated with the dynamic light scattering technique at pH 5 (0.05 M acetate buffer) and pH 7 (water) using the Zetasizer Nano instrument (Malvern, UK). Measurements were performed for 1 mg/mL samples (0.06–0.1 mM solutions).

2.7. Biological Studies

2.7.1. Cell Cultures

Human cancer cell lines: U-118 MG (glioblastoma multiforme, grade IV) and SCC-15 (squamous cell carcinoma) were grown in DMEM and DMEM/F-12 with hydrocortisone (400 ng/mL), respectively. Normal human skin fibroblasts (BJ) were cultured in EMEM. Growth media were supplemented with heat-inactivated 10% FBS and 100 U/mL penicillin and 1% streptomycin solution. Cells were cultured at 37 °C in a humidified 95% air/5% CO₂ with growth media changed every 2–3 days. Cells were passaged at 75%–85% confluence using 0.25% trypsin–0.03% EDTA in PBS (calcium and magnesium ions free). The morphology of cells was observed under a Nikon TE2000S Inverted Microscope with phase contrast (Tokyo, Japan). The number and viability of cells were estimated by a trypan blue exclusion test using an Automatic Cell Counter TC20 (BioRad Laboratories, Hercules, CA, USA) or a Neubauer chamber. All assays were performed in triplicates in three independent experiments. The working solutions of the synthesized dendrimer conjugates and the drugs alone were prepared from stock solutions in cell culture media with an adjusted concentration of DMSO. Control samples with non-treated cells in a complete culture medium with adjusted DMSO concentration were included in all biological tests.

2.7.2. Cytotoxicity

The cytotoxicity of αM , V, and their conjugates with PAMAM G3 modified dendrimer ($G3^{gh2B5M}$, $G3^{2B12gh5M}$, $G3^{gh4B5V}$ and $G3^{2B12gh5V}$) was examined with neutral red (NR) uptake assay or XTT reduction assay. BJ, U-118 MG and SCC-15 cells were seeded in flat, clear bottom 96-well plates in triplicate (100 μ L of cell suspension/well) at a density of 1×10^4 cells/well and left for 24 h to attach. Then, culture medium was removed and cells were incubated in 37 °C with 100 μ L of working solutions of αM , V, $G3^{gh2B5M}$, $G3^{2B12gh5M}$,

G3^{gh4B5V} or **G3^{2B12gh5V}** for 48 h. After that, NR or XTT assays were performed as earlier described [31].

2.7.3. Proliferation

Cells proliferation was estimated using Hoechst 33,342 staining. BJ, U-118 MG and SCC-15 cells at a density of 5×10^3 /well were seeded into 96-well plates and incubated for 24 h at 37 °C to attach. Then, following the culture medium removal, cells were incubated with 100 µL of working solutions of the studied drugs or dendrimer conjugates for 72 h. Afterwards, plates were centrifuged (5 min, 700 g) and the working solutions of studied compounds removed. Cells were fixed in 3.7% formaldehyde solution in PBS for 10 min at room temperature and again centrifuged followed by staining with 1 µg/mL Hoechst 33,342 solution in PBS (100 µL, 1 h). The fluorescence signal was measured using Tecan Infinite M200 PRO Multimode Microplate Reader (TECAN Group Ltd., Männedorf, Switzerland) at 350/461 nm.

2.7.4. Toxicity to *Caenorhabditis elegans* and the Worm Survival Analysis

Caenorhabditis elegans nematodes (wild type strain N2, variety Bristol) were cultured at 20 °C on NGM agar plates with *E. coli* OP50 lawn as a food source [40]. Worm survival analysis was performed as described in [29].

2.7.5. Statistical Analysis

In order to estimate the differences between treated cells and non-treated control groups, statistical analysis was performed using the non-parametric Kruskal-Wallis test due to the lack of a normal distribution of the data. To determine the statistically significant differences between the ester conjugate-treated group (**G3^{gh2B5M}** or **G3^{gh4B5V}**) against the amide conjugate-treated group (**G3^{2B12gh5M}** or **G3^{2B12gh5V}**), a Mann–Whitney U test was applied ($p \leq 0.05$ was considered statistically significant). The survival curves of *C. elegans* nematodes were presented in a plot of the Kaplan–Meier estimator. Gehan’s Wilcoxon test was used to assess statistically significant differences (with $p \leq 0.05$) between treated and non-treated control nematodes. All analyses and calculations were performed with Statistica 13.3 software (StatSoft Poland, Cracow).

3. Results and Discussion

3.1. Syntheses and Characterization of Dendrimer Conjugates

The PAMAM G3 dendrimer was converted by exhaustive glucoheptoamidation with GHL as described before [39] to obtain **G3^{gh}** (Scheme 1A). This 2 nm sized dendrimer was then used as a core to attach αM or V and biotin (B). The αM was modified by ester attachment of succinyl linker (αM-Suc) via 6-O (Scheme 1B) as was determined before [39]. At the step of conjugate formation, the carboxyl groups of αM-Suc or V, and B were activated efficiently with Mukaiyama reagent (2-chloro-1-methylpyridinium iodide) in the presence of 4-(dimethylamino)pyridine (DMAP), enabling further reaction with the **G3^{gh}** core hydroxyl groups. Mukaiyama reagent is commonly used for synthesis of esters, lactones, amides and ketenes, causing activation of hydroxyl groups of carboxylic acids and alcohols [41]. The products were isolated by extensive removal of low molecular reagents and side-products by dialysis and were characterized by NMR spectroscopy and DLS. The synthesis pathway and conjugate formula with atom numbering are presented in Scheme 2.

The ¹H NMR spectrum of **G3^{gh}** dendrimer conjugated with αM and biotin via ester bonds is presented in Figure 1B compared to αM alone (Figure 1A) (both measurements were performed in DMSO-d₆).




Figure 1. The ^1H NMR spectra of α -mangostin (A) and $\text{G3}^{\text{gh2B5M}}$ conjugate (B) in DMSO-d_6 . The residual solvent peak at 2.5 ppm and impurity resonances are marked with asterisks *. The PAMAM G3 core dendrimer resonances are labeled as $\text{CH}_2(\text{G3})$ and $\text{NH}(\text{G3})$ in spectrum B. The resonances of α -mangostin, biotin, and glucoheptoamide are labeled by locants with $^{\text{M}}$, $^{\text{B}}$, and $^{\text{gh}}$ upper indexes, respectively, according to the atom numbering in Scheme 2. The 1A spectrum was taken from [29].

Additional 2-D COSY, HSQC and HMBC measurements were performed (Figures S1 and S2) and allowed for detailed assignments of ^1H and ^{13}C resonances (Table S1). The number of attached residues of αM and B to G3^{gh} dendrimer was estimated based upon the integral intensity of αM aromatic protons (5^{M} at 6.79 ppm and 4^{M} at 6.34 ppm) and one free hydroxyl proton ($1'^{\text{M}}$ at 13.73 ppm) resonances, and B resonances (10^{B} and 11^{B} at 6.48 and 6.40 ppm) in relation to the reference intensity of b_{0-3} protons resonance from the dendrimer core, namely [120H] (for detailed assignment of protons from internal PAMAM G3 arms see Figure 2 in [29]). The averaged final product was identified as $\text{G3}^{\text{gh2B5M}}$. In its ^1H -NMR spectrum, the characteristic resonances of αM protons are observed and retained the same chemical shifts as resonances of protons recorded in αM alone. Proton resonances from $3'^{\text{M}}$ and $6'^{\text{M}}$ hydroxyl groups were not detected, while singlet resonance at 13.73 ppm corresponding to the third hydroxyl group proton ($1'^{\text{M}}$) was found. It suggests that either of the $3'^{\text{M}}$ and $6'^{\text{M}}$ protons participate in bonding to G3^{gh} dendrimer.

The ^1H NMR spectrum of G3^{gh} conjugated with vadimezan and biotin is shown in Figure 2B in comparison with vadimezan (Figure 2A) (both in DMSO-d_6), while detailed NMR spectral assignments were performed by 2-D COSY, HSQC, and HMBC measure-

ments as presented in Figure S3 (COSY) and Figure S4 (combined heteronuclear ^1H - ^{13}C HSQC/HMBC) with Table S1.




Figure 2. The ^1H NMR spectra of vadimezan (A), $\text{G3}^{\text{gh4B5V}}$ (B) and $\text{G3}^{2\text{B12gh5V}}$ (C) conjugates in DMSO-d_6 . The residual solvent peak at 2.5 ppm is marked with asterisks *. The PAMAM G3 core dendrimer resonances are labeled as $\text{CH}_2(\text{G3})$ and $\text{NH}(\text{G3})$ in spectrum B and C. The resonances of vadimezan, biotin, and glucoheptoamide are labeled by locants with $^{\text{V}}$, $^{\text{B}}$, and $^{\text{gh}}$ upper indexes, respectively, according to the atom numbering in Schemes 2 and 3.

The stoichiometry of conjugate was determined by a comparison of integral intensity of V aromatic proton resonances (2^{V} and 7^{V}) at 7.50–7.15 ppm, and B resonances (10^{B} and 11^{B} at 6.50–6.35 ppm) versus $\text{CH}_2(\text{b}_{0-3})$ PAMAM G3 core resonance centered at 2.20 ppm ([120H]); additional intensity comes from 4 biotin CH_2 multiplet identified in COSY (Figure S3, cross-peak q). The average conjugate was identified as $\text{G3}^{\text{gh4B5V}}$. Only 2^{V} and 7^{V} aromatic protons resonances were recorded as isolated signals, while the remaining signals

of vadimezan protons are overlapped by resonances of dendrimer and gh protons. 2-D COSY, HSQC and HMBC measurements allowed for detailed assignment of each signal. It is worth noting that within glucoheptoamide residues the CH resonances were identified unambiguously (in COSY cross-peak j is between 2^{gh} and 3^{gh}), while scalar couplings within hydroxymethylene groups HO-C-H were observed (cross-peaks e, f, h, and g in COSY experiment, see Figure S3), which enabled to combine vicinal OH and H in gh residues (Table S1).

PAMAM G3 dendrimer conjugate with amide-bonded vadimezan, biotin, and GHL was synthesized to compare its activity with that of the αM dendrimer conjugate ($\text{G3}^{2\text{B12gh5M}}$) obtained and described earlier [29]. As in the synthesis of the ester conjugates described above, Mukaiyama reagent was also used in the synthesis of the amide conjugate with V. In this procedure, native PAMAM G3 was used as a conjugate core. In the presence of Mukaiyama reagent and DMAP, amine groups from the dendrimer surface were able to react with carboxyl groups of V and B. The intermediate product, isolated by dialysis and characterized by NMR spectroscopy, was identified as $\text{G3}^{2\text{B5V}}$ and further converted into half-glucoheptoamidated derivative by the substitution of half of the remaining amine groups with GHL. The synthesis pathway and conjugate formula with atom numbering are presented in Scheme 3. The ^1H NMR spectrum of the conjugate in DMSO-d_6 is shown in Figure 2C. The stoichiometry of the conjugate was estimated in the same way as described above for ester-bonded vadimezan conjugate and allowed us to identify product as $\text{G3}^{2\text{B12gh5V}}$.

The conjugates were obtained in rather low yield (<55%) due to compromising it against the high purity reached by extensive dialysis.

3.2. Size and ζ Potential of Dendrimer Conjugates

DLS measurements were performed to determine the size and zeta potential of the synthesized conjugates. Obtained values are collected in Table 1 and illustrated in Figures S5 and S6.

Table 1. Size of conjugates averaged by volume (d(V)) and by number of molecules (d(N)) and zeta potential values \pm standard deviation determined by DLS analysis.

Compound	Size [nm]				Zeta Potential [mV]	
	pH 7		pH 5		pH 7	pH 5
	d(V)	d(N)	d(V)	d(N)		
G3^{gh}	1.7 ± 0.44	1.5 ± 0.51	4.3 ± 0.34	3.6 ± 0.32	4.5 ± 0.58	5.3 ± 0.81
$\text{G3}^{\text{gh2B5M}}$	155.1 ± 3.46	113 ± 5.89	212.7 ± 4.29	144.5 ± 6.49	10 ± 0.39	24.9 ± 1.78
$\text{G3}^{2\text{B12gh5M}}$ [29]	1367 ± 245.7	1262 ± 196.4	178.3 ± 5.73	113.8 ± 7.34	22.7 ± 1.01	37.5 ± 2.32
$\text{G3}^{\text{gh4B5V}}$	3.7 ± 0.23	2.9 ± 0.56	4.9 ± 0.14	4.2 ± 0.18	7.6 ± 4.35	6.2 ± 0.81
$\text{G3}^{2\text{B12gh5V}}$	1166 ± 153	970.4 ± 81.6	1090 ± 39.2	924.4 ± 39	22.8 ± 0.69	33.4 ± 2.82

The dynamic diameter of G3^{gh} in an aqueous solution is 1.5 nm (averaged by number) or 1.7 nm (averaged by volume), which is nearly two-fold smaller than diameter of the native PAMAM G3. In the acidic environment (pH 5) the diameter of G3^{gh} increases to 3.6 nm (d(N)) or 4.3 nm (d(V)) upon protonation of internal tertiary amine groups, which was observed earlier for the series of G3 substituted with variable amount of gh residues [42]. Slightly higher dynamic diameter of $\text{G3}^{\text{gh4B5V}}$ conjugate, equal 2.9 nm (by number) or 3.7 nm (by volume) in water and 4.2 nm (d(N)) or 4.9 nm (d(V)) in pH 5, indicates that this conjugate is dispersed at unimolecular level. The other conjugates were associated both in pH 7 and pH 5, with the strongest effect observed for $\text{G3}^{2\text{B12gh5M}}$ and $\text{G3}^{2\text{B12gh5V}}$. The molecules of the ester conjugate $\text{G3}^{\text{gh2B5M}}$ also associate but particle size is 10 times smaller than that of the amide $\text{G3}^{2\text{B12gh5M}}$ analogue. However, the particle size of $\text{G3}^{2\text{B12gh5M}}$ was reduced by seven times upon a pH decrease from 7 to 5. This effect can be attributed to the presence of ca. 12 free amine groups in the $\text{G3}^{2\text{B12gh5M}}$ conjugate which are readily to protonate, while amine groups in ester conjugate are fully glucoheptoamidated.

All studied conjugates have positive zeta potential. For conjugates with small molecular size, $G3^{gh}$ and $G3^{gh4B5V}$ zeta potential values are <10 mV and increase with the conjugates diameter up to 33.4 mV and 37.5 mV for $G3^{2B12gh5V}$ and $G3^{2B12gh5M}$, respectively. It is also worth noting that amide conjugates, $G3^{2B12gh5M}$ and $G3^{2B12gh5V}$ have comparable zeta potential and particle size but they differ in biological activity (vide infra). Due to the fact that the cell membrane is negatively charged, nanoparticles with positive net charge have a greater ability to enter and penetrate cells [43].

3.3. Cytotoxicity

The NR and XTT assays revealed that vadimezan (V) after 48 h incubation showed no cytotoxic effect against any studied cell line (BJ, SCC-15 and U-118 MG) up to 200 μ M concentration (Table 2). Vadimezan is a Vascular Disrupting Agent (VDA) whose anticancer action, based mainly on an irreversible destruction of established tumor vessels and tumor blood flow arrest, has been observed mainly in the endothelial cells where it induced apoptosis [14]. However, the present results do not indicate V to lower viability of cells, including epithelial cancer cells (SCC-15). Our results are consistent with other, pointing to the drug's selective toxicity against vascular endothelial cells. Using the MTT assay, Zhang et al. [44] showed that V did not disturb the mitochondrial metabolism of any of ten cell lines (Ishikawa, A549, Bewo, HeLa, Siha, MCF-7, HL-60, BEL-7402, NCI-460, BGC-823) after 48 h incubation. Lv et al. [45] also found free V (up to 35.4 μ M) to be non-toxic to breast carcinoma MCF-7 cells, lung carcinoma A549 cells and mouse embryo fibroblast NIH/3T3 cells after 48 h treatment. Only human vein umbilical cell (HUVEC) growth was demonstrated to undergo inhibition by vadimezan ($IC_{50} > 20 \mu$ M) [44]. On the other hand, the delivery of nanoparticles (mPEG-*b*-PHEA) conjugated with V and encapsulated with DOX resulted in cytotoxicity to both tumorous and nontumorous cells. Furthermore, those nanoparticles equipped with V and DOX showed a similar inhibition of cells proliferation to free DOX [45].

Table 2. The half maximal inhibitory concentration (IC_{50}) values estimated with NR and XTT assay after 48 h incubation of BJ, U-118 MG and SCC-15 cells with α M or V, each used either as a free drug or the dendrimer conjugate. The IC_{50} values were calculated with AAT Bioquest IC_{50} calculator [46].

IC_{50} [μ M] NR Assay			
	BJ	U-118 MG	SCC-15
α -mangostin [2]	8.97	9.59	6.43
$G3^{gh2B5M}$	2.02	2.52	1.7
$G3^{2B12gh5M}$ [29]	2	1.83	1.41
Vadimezan	>>200	>>200	>>200
$G3^{gh4B5V}$	>>24	>>24	>>24
$G3^{2B12gh5V}$	>>12	>>12	>>12
IC_{50} [μ M] XTT Assay			
	BJ	U-118 MG	SCC-15
α -mangostin [2]	18.58	18.15	7.72
$G3^{gh2B5M}$	3.36	4.14	3.02
$G3^{2B12gh5M}$ [29]	2.37	2.05	2.52
Vadimezan	>>200	>>200	>200
$G3^{gh4B5V}$	>>24	>>24	>>24
$G3^{2B12gh5V}$	>>12	>>12	>>12

The anticancer activity of xanthenes depends on the type, number, and position of the attached functional groups in their skeleton [47]. Anticancer activity of α M seems to depend on the presence of two isoprenyl groups localized on 2-nd and 8-th carbon in xanthenone ring [29], not present in vadimezan. Castanheiro et al. [48] showed that the introduction of the prenyl group to the 1-hydroxyxanthenone markedly increased its anticancer activity against the MCF-7 cell line, in accordance with the presence of prenyl groups being associated with an improvement of potency and selectivity of xanthenes [49].

At present, prenylated xanthenes are the most valued xanthenes, in view of their promising properties as active and selective anticancer agents [47].

The present results reflect an attempt to increase the anti-tumor activity of V and α M by covalent binding the drugs to biotinylated PAMAM G3 dendrimers, demonstrated previously to be effective in this respect [50]. Cytotoxicity assays revealed that vadimezan attached to biotinylated and glucoheptoamidated PAMAMs did not exert any significant inhibitory activity (up to 24 μ M $G3^{gh4B5V}$ or 12 μ M $G3^{2B12gh5V}$ after 48 h incubation (Table 2, Figures 3 and 4). It should be added that the latter observation provided additional evidence that the applied V vehicles do not show biological activity (cf. Figure S7 for $G3^{gh}$ and [29] for $G3^{2B12gh}$). Of note is (Figures 3 and 4) that 4–12 μ M $G3^{2B12gh5V}$ lowered SCC-15 cell viability down to 80% (apparent only in the XTT assay) and 2–12 μ M $G3^{gh4B5V}$ increased BJ cell viability by 25–40% (apparent only in the NR assay). This effect might be caused by changes in cell proliferation rate, as discussed below.

NR




Figure 3. Cytotoxic effect of dendrimers conjugated via ester or amide bond with α M ($G3^{gh2B5M}$ and $G3^{2B12gh5M}$) and V ($G3^{gh4B5V}$ and $G3^{2B12gh5V}$) after 48 h of incubation with normal fibroblasts (BJ), glioblastoma cells (U-118 MG), and squamous carcinoma cells (SCC-15), estimated with the NR assay. Cell viability (expressed as percent of the non-treated control) medians are plotted. The whiskers are lower (25%) and upper (75%) quartile ranges. * $p \leq 0.05$; Kruskal-Wallis test (against non-treated control), $\dagger p \leq 0.05$; Mann-Whitney U test (ester against amide-attached drug-conjugate). ¹ Data for $G3^{2B12gh5M}$ were reproduced from [29].




Figure 4. Viability of normal fibroblasts (BJ), glioblastoma cells (U-118 MG) and squamous carcinoma cells (SCC-15) after 48 h of incubation with $G3^{gh2B5M}$, $G3^{2B12gh5M1}$, $G3^{gh4B5V}$ and $G3^{2B12gh5V}$, assessed by XTT assay. Cells viability (expressed as percent of the non-treated control) medians are plotted. The whiskers are lower (25%) and upper (75%) quartile ranges. * $p \leq 0.05$; Kruskal-Wallis test (against non-treated control), $\downarrow p \leq 0.05$; Mann-Whitney U test (ester- against amide-attached drug-conjugate). ¹ Data for $G3^{2B12gh5M}$ were reproduced from [29].

The activity of αM increased significantly after attaching it to the studied carriers. The action of conjugate $G3^{2B12gh5M}$ was slightly stronger than $G3^{gh2B5M}$ with an IC_{50} of approx. 1.4–2 μM (NR assay) and 2–2.5 μM (XTT assay) for all studied cell lines. The largest differences were observed in glioma cells, where $G3^{2B12gh5M}$ acted two-fold stronger than $G3^{gh2B5M}$. Moreover, the strongest effect of both conjugates was still observed in SCC-15 cells (Table 2, Figures 3 and 4).

The greater effect of an αM -amide conjugated dendrimer may result from the fact that it has free amino groups responsible for the cytotoxic effect. As it was presented in Section 3.2. the zeta potential of the $G3^{2B12gh5M}$ conjugate was higher than that of $G3^{gh2B5M}$. It could be the reason of a higher activity of the former, since dendrimers with higher zeta potential and surface charge indicate higher cytotoxicity also in consequence of more efficient cellular uptake [51,52]. An important issue is the mechanism of possible enzymatic degradation of amide or ester bonds in conjugates with the participation of lysosomal or other intracellular enzymes and the consequent release of attached drugs. Kurtoglu et al. have shown that PAMAM dendrimer-ibuprofen conjugates with ester or amide linkers differ in the degree of drug release. Amide and ester-linked conjugates were very stable after 48 h of incubation in buffer. The ester-linked conjugates showed pH-dependent release and the extent of release varied with pH from 3% (pH 5) to 38% (pH 8.5) within a 10-day studied period. Moreover, direct amide- and ester-linked conjugates did

not release ibuprofen enzymatically in cathepsin B buffer and diluted human plasma [28]. This means that the incubation time of both tested dendrimers (**G3^{2B12gh5M}** and **G3^{gh2B5M}**) with cells in FBS containing medium was too short to observe significant differences in the release of α M from the conjugates. This was also confirmed by the results of our previous studies concerning the release of doxorubicin conjugated through amide linker to glucoheptoamidated PAMAM G3 dendrimer [39]. Although ester bonds are generally easy to hydrolyze (such as carboxylate ester bond), some ester structures, such as alkyl esters, hydrolyze very slowly, even in the presence of esterase [27]. This could be the reason of weaker activity of dendrimeric conjugates with ester-bonded α M. Quintana et al. [53] and Thomas et al. [54] used, as a model drug, methotrexate (MTX), having two available functional groups for conjugation, carboxylic and amine, in order to examine the effect of the type of chemical bond on the conjugate activity. MTX conjugated to acetamide-functionalized G5 PAMAM dendrimer through ester bond was found four times more active than free MTX, whereas MTX conjugated via amide bonds to the same dendrimer was less active compared to free MTX. However, in this case, changing the binding site of the drug molecule may induce changes in its activity.

An important factor influencing the toxicity of nanoparticles is the efficiency and the pathway they enter cells that depends on their size and charge. All studied conjugates indicated positive charge on their surface. The smallest conjugates (**G3^{gh}** and **G3^{gh4B5V}**) can probably enter cells through passive uptake, while slightly larger compound **G3^{gh2B5M}** (ca. 113 nm diameter) via clathrin-mediated endocytosis. In the case of **G3^{2B12gh5M}** and **G3^{2B12gh5V}** conjugates, the most possible route of internalization seems to be phagocytosis and/or micropinocytosis (associates diameter ca. 1000–1300 nm) [55]. This phenomenon requires further research.

3.4. Proliferation

There are no clear examples of the antiproliferative activity of vadimezan in the available literature, which suggests that such properties were not observed at therapeutic concentrations. One paper showed that the combination of tCoa-NGR fusion proteins with V suppressed the growth and proliferation of B16-F10 melanoma tumors in C57/BL6 mice [56]. In our studies, V inhibited the proliferation of cancer SCC-15 cells from 100 μ M concentration and U-118 MG glioma cells from 200 μ M, but not normal cells (Figure 5). PAMAM G3 dendrimer, biotinylated and partially glucoheptoamidated with V bound via amide linker (**G3^{2B12gh5V}**), enhanced its anti-proliferative activity by as much as 50-fold. This construct distinctly limited proliferation of SCC-15 and U-118 MG cells when applied at concentrations 2 and 12 μ M, respectively. This effect apparently was related to the decrease of mitochondrial efficiency observed at 4–12 μ M **G3^{2B12gh5V}** in SCC-15 and U-118 MG cells (Figure 4). Of note is that in normal BJ cells **G3^{2B12gh5V}** rather promoted cell proliferation at 8 and 12 μ M concentrations (Figure 5), suggesting **G3^{2B12gh}** vehicle to be responsible for this effect, as it significantly increased fibroblasts growth at the 5–20 μ M range of concentrations [29]. No effect was observed with the conjugate containing the ester linkage (**G3^{gh4B5V}**), despite the fact that the 20 μ M **G3^{gh}** vehicle itself showed a weak anti-proliferative effect against SCC-15 cells (Figure S7, part C). The size and zeta potential of the studied conjugates may be important factors influencing their properties, as the **G3^{2B12gh5V}**, compared to **G3^{gh4B5V}** conjugate, showed higher activity and formed associations with diameter at pH 7 being about 300-fold larger (about 1000–1200 nm vs. 2.90–3.7 nm). Thus, it may increase the polyvalence of conjugates, which is responsible for their increased activity [57]. The size of the molecule and the presence of free amino groups on the **G3^{2B12gh5V}** surface corresponded to its 3-fold higher zeta potential, responsible for a stronger toxicity of dendrimers [51]. However, it seems that this was a rather minor effect, since this phenomenon was not seen in normal BJ fibroblasts (BJ cells are more sensitive to high surface charge of dendrimers than SCC-15 cancer cells [58]).




Figure 5. Anti-proliferative effect of $G3gh2B5M$, $G32B12gh5M$, $G3gh4B5V$, $G32B12gh5V$, αM , and V on BJ, U-118 MG, and SCC-15 cells after 72 h of incubation, determined with Hoechst 33,342 staining. Medians of the fluorescence signal (expressed as percent of the non-treated control), indicating the cell number in a well, are plotted. The whiskers indicate lower (25%) and upper (75%) quartile ranges. * $p \leq 0.05$; Kruskal-Wallis test (against non-treated control), $\uparrow p \leq 0.05$; Mann-Whitney U test (ester against amide-attached drug-conjugate). ^{1,2} Data for $G32B12gh5M$ conjugate and αM were reproduced from [2,29], respectively.

Unlike vadimezan, αM is a well-known anti-proliferative agent. The inhibition of cell proliferation induced by αM led to G1-phase arrest and S-phase suppression in MDA-MB231 human breast cancer cells with altering the expression of cell-cycle-related molecules, such as p21^{cip1}, CHEK2, cyclins, CDKs, and PCNA [59]. The G0/G1 phase arrest and the G1 arrest caused by αM was also observed in four hepatocellular carcinoma (HCC) cell lines [9] and human oral squamous carcinoma cells (OSCC) [60], respectively. In our study, the proliferation of cancer cells (U-118 MG and SCC-15) and normal BJ fibroblasts was studied after 72 h of incubation with each of the xanthenes (αM and V) and their dendrimer conjugates. The results are presented in Figure 5 and demonstrate anti-proliferative activity of αM in the concentration range of 7.5–20 μM [2]. The strongest inhibition of proliferation was observed for SCC-15 cells (reduction to 12% at 20 μM), slightly weaker for glioma cells (reduction to 17% at 20 μM) and the weakest for normal fibroblasts (reduction to 49% at 20 μM).

Conjugation of biotinylated dendrimers with 5 residues of αM enhanced its anti-proliferative activity against both cancer and normal cell lines, with the $G3gh2B5M$ ester conjugate acting slightly weaker (over 3-fold enhancement) than the $G32B12gh5M$ amide conjugate (over 5-fold enhancement). The proliferation of SCC-15 cells underwent the strongest inhibition by these two αM conjugates (almost no viable cells at 3 and 4 μM , respectively). The latter effect was less pronounced in the case of normal cells (30% viable cells at 3 μM $G3gh2B5M$ and 34% viable cells at 2 μM $G32B12gh5M$), with glioblastoma cells being the least sensitive (49% and 16% at 3 μM $G3gh2B5M$ and $G32B12gh5M$, respectively). The most significant difference in suppression of cell growth elicited by αM ester or amide conjugates was observed with fibroblasts (74% and 33% viable cells at 2 μM $G3gh2B5M$ and $G32B12gh5M$, respectively).

3.5. Toxicity against *C. elegans* and the Effect on the Worm Survival

Biological activities of α M and V, used as free compounds or their dendrimer conjugates, were also evaluated with a model nematode, *Caenorhabditis elegans*, a cost-effective and powerful model widely used for screening of bioactive compounds prior to be tested with higher animals [37]. *C. elegans* has been previously used in studies on the toxicity of drug-loaded nanoparticles, such as glibenclamide-loaded PVM/MA (poly(methylvinyl ether-co-maleic anhydride)) nanoparticles for oral delivery purposes [61], insulin-loaded PPA (PEG-polu(anhydride) conjugate) nanoparticles with the ability to mucus permeation for the oral administration of insulin [62], and the toxicity of bare nanoparticles, for example, zinc oxide nanoparticles (ZnO-NPs) [63] and gold nanoparticles (AuNPs) [64].

We used synchronized population of L4-stage nematodes to examine survivability and general toxicity after 7 days of incubation with free α M or V, and with their dendrimer conjugates: $G3^{gh2B5M}$, $G3^{2B12gh5M}$, $G3^{gh4B5V}$, $G3^{2B12gh5V}$ at different concentration ranges. The results of worms' survival are shown in Figure 6 and in Table 3 (LC₅₀ values).




Figure 6. The Kaplan-Meier survival curves of *C. elegans* after 7 days of incubation with α M, V, $G3^{gh2B5M}$, $G3^{2B12gh5M}$, $G3^{gh4B5V}$ or $G3^{2B12gh5V}$. Results are presented as cumulative proportion surviving. Statistically significant differences against dms0-treated control obtained in Gehan's Wilcoxon test are marked with asterisks * ($p \leq 0.05$) in the colours corresponding to the tested concentrations.^{1,2} Data for α M and $G3^{2B12gh5M}$ conjugate were reproduced from [2,29], respectively.

Table 3. The half maximal lethal concentration (LC₅₀) values estimated after 7 days incubation of *C. elegans* nematodes with free α M and V, or their dendrimer conjugates. Data are presented as medians with the first and third quartile. Presented values were calculated with AAT Bioquest IC₅₀ calculator [46].

	LC ₅₀ [μ M]	1st Quartile	3rd Quartile
α -Mangostin [2]	18.74	18.64	20.23
G3^{gh2B5M}	>16	>16	>16
G3^{2B12gh5M} [29]	7.87	4.95	8.09
Vadimezan	>>200	>>200	>>200
G3^{gh4B5V}	>>24	>>24	>>24'
G3^{2B12gh5V}	>>12	>>12	>>12

Free V exhibited no toxicity against *C. elegans* up to 200 μ M concentration with a cumulative proportion surviving equal to 90%. The conjugation of V to the dendrimer by either ester or amide bonds also did not increase its toxicity. On the other hand, α M caused a toxic effect with the LC₅₀ value, the minimum being over 10 times higher than that of V (comparing LC₅₀ values). This confirms that the presence of prenyl residues in α M structure has a significant influence on its toxicity in vivo. Substitution of α M with biotinylated and glucoheptoamidated dendrimers via ester linker (**G3^{gh2B5M}**) increased its toxicity only by 20%, while conjugate with amide-bonded α M (**G3^{2B12gh5M}**) was more active by 140% comparing to free α M (Table 3). Additionally, **G3^{gh2B5M}** conjugate showed two-fold weaker activity than **G3^{2B12gh5M}** in the worm.

4. Conclusions

Similar toxicity profiles of the tested conjugates in vitro and in vivo allow us to conclude that the main factors influencing the differences in the activity of evaluated agents were: differences in the value of the zeta potential and the size of the nanoparticles, as well as the presence of various linkers (amide or ester). The results clearly show that conjugates containing amide bonds, partially-blocked amino groups on the surface, larger particle diameters and higher zeta potentials could be a more effective tool for therapy for cancer and nematode infections. Considering the vadimezan mechanism of action, based on its selective effect on blood vessel cells in the tumor environment, conjugates with vadimezan are still valuable research objects. An antiproliferative effect of **G3^{2B12gh5V}** in vitro against cancer, but not normal cells, is also interesting. Therefore, the proposed drug delivery system based on the PAMAM G3 dendrimer with partially-blocked amine groups on the surface can be a useful tool to improve the biological properties of transported drug molecules. Further studies on the in vivo model with implanted and perfused tumors are necessary.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmaceutics14030606/s1>, Figure S1: The ¹H-¹H COSY spectrum of **G3^{gh2B5M}** in DMSO-d₆; Figure S2: The HSQC/HMBC combined spectra for **G3^{gh2B5M}** in DMSO-d₆; Figure S3: The ¹H-¹H COSY spectrum of **G3^{gh4B5V}** in DMSO-d₆; Figure S4: The HSQC/HMBC combined spectra for **G3^{gh4B5V}** in DMSO-d₆; Figure S5: Diameter of conjugates averaged by volume (d(V)) and by number of molecules (d(N)) measured in water (A) and in acetate buffer pH 5 (B); Figure S6: Zeta potential of conjugates measured in water (pH 7) and acetate buffer (pH 5); Figure S7: Cytotoxicity of **G3^{gh}** vehicle estimated with NR (A) and XTT (B) assay after 48 h incubation with normal fibroblasts (BJ), glioblastoma cells (U-118 MG) and squamous carcinoma cells (SCC-15); Table S1: The ¹H and ¹³C resonance assignments of the **G3^{gh4B5V}**, V, **G3^{gh2B5M}** and α M based on COSY and HSQC/HMBC spectra in DMSO-d₆.

Author Contributions: Conceptualization, J.M., W.R. and Ł.U.; methodology, S.W. and Ł.U.; software, J.M.; validation, J.M., S.W. and Ł.U.; formal analysis, W.R. and Ł.U.; investigation, J.M., S.W. and Ł.U.; resources, S.W., W.R. and Ł.U.; data curation, J.M., S.W. and Ł.U.; writing—original draft preparation, J.M., S.W. and Ł.U.; writing—review and editing, J.M., S.W., W.R. and Ł.U.; visualization,

J.M.; supervision, S.W., W.R. and Ł.U.; project administration, J.M. and Ł.U.; funding acquisition, W.R. and Ł.U. All authors have read and agreed to the published version of the manuscript.

Funding: Supported by the National Science Center, Poland, grant no. 2016/21/B/NZ1/00288.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data supporting the reported results are available on request from the corresponding author.

Acknowledgments: The kind support by Małgorzata Walczak from the Rzeszów University of Technology to enable us to perform DLS measurements is gratefully acknowledged.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ho, L.Y.; Lim, Y.Y.; Tan, C.P.; Siow, L.F. Comparison of physicochemical properties and aqueous solubility of xanthone prepared via oil-in-water emulsion and complex coacervation techniques. *Int. J. Food Prop.* **2018**, *21*, 784–798. [\[CrossRef\]](#)
2. Markowicz, J.; Uram, Ł.; Sobich, J.; Mangiardi, L.; Maj, P.; Rode, W. Antitumor and anti-nematode activities of α -mangostin. *Eur. J. Pharmacol.* **2019**, *863*, 172678. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Aukkanimart, R.; Boonmars, T.; Sriraj, P.; Sripan, P.; Songsri, J.; Ratanasuwan, P.; Laummaunwai, P.; Boueroy, P.; Khueangchaingkhwang, S.; Pumhirunroj, B.; et al. In Vitro and in Vivo Inhibitory Effects of α -Mangostin on Cholangiocarcinoma Cells and Allografts. *Asian Pac. J. Cancer Prev.* **2017**, *18*, 707–713. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Beninati, S.; Oliverio, S.; Cordella, M.; Rossi, S.; Senatore, C.; Liguori, I.; Lentini, A.; Piredda, L.; Tabolacci, C. Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α -mangostin. *Biochem. Biophys. Res. Commun.* **2014**, *450*, 1512–1517. [\[CrossRef\]](#)
5. Hsieh, S.-C.; Huang, M.-H.; Cheng, C.-W.; Hung, J.-H.; Yang, S.-F.; Hsieh, Y.-H. α -Mangostin induces mitochondrial dependent apoptosis in human hepatoma SK-Hep-1 cells through inhibition of p38 MAPK pathway. *Apoptosis* **2013**, *18*, 1548–1560. [\[CrossRef\]](#)
6. Shibata, M.-A.; Iinuma, M.; Morimoto, J.; Kurose, H.; Akamatsu, K.; Okuno, Y.; Akao, Y.; Otsuki, Y. α -Mangostin extracted from the pericarp of the mangosteen (*Garcinia mangostana* Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation. *BMC Med.* **2011**, *9*, 69. [\[CrossRef\]](#)
7. Chao, A.-C.; Hsu, Y.-L.; Liu, C.-K.; Kuo, P.-L. α -Mangostin, a Dietary Xanthone, Induces Autophagic Cell Death by Activating the AMP-Activated Protein Kinase Pathway in Glioblastoma Cells. *J. Agric. Food Chem.* **2011**, *59*, 2086–2096. [\[CrossRef\]](#)
8. Bin Hafeez, B.; Mustafa, A.; Fischer, J.W.; Singh, A.; Zhong, W.; Shekhani, M.O.; Meske, L.; Havighurst, T.; Kim, K.; Verma, A.K. α -Mangostin: A Dietary Antioxidant Derived from the Pericarp of *Garcinia mangostana* L. Inhibits Pancreatic Tumor Growth in Xenograft Mouse Model. *Antioxid. Redox Signal.* **2014**, *21*, 682–699. [\[CrossRef\]](#)
9. Cai, N.; Xie, S.-J.; Qiu, D.-B.; Jia, C.-C.; Du, C.; Liu, W.; Chen, J.-J.; Zhang, Q. Potential effects of α -mangostin in the prevention and treatment of hepatocellular carcinoma. *J. Funct. Foods* **2016**, *26*, 309–318. [\[CrossRef\]](#)
10. Lee, C.-H.; Ying, T.-H.; Chiou, H.-L.; Hsieh, S.-C.; Wen, S.-H.; Chou, R.-H.; Hsieh, Y.-H. Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells. *Oncotarget* **2017**, *8*, 47425–47439. [\[CrossRef\]](#)
11. Johnson, J.J.; Petiwala, S.M.; Syed, D.N.; Rasmussen, J.T.; Adhami, V.M.; Siddiqui, I.A.; Kohl, A.M.; Mukhtar, H. α -Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth. *Carcinogenesis* **2011**, *33*, 413–419. [\[CrossRef\]](#)
12. Chitchumroonchokchai, C.; Thomas-Ahner, J.M.; Li, J.; Riedl, K.M.; Nontakham, J.; Suksumrarn, S.; Clinton, S.K.; Kinghorn, A.D.; Failla, M.L. Anti-tumorigenicity of dietary α -mangostin in an HT-29 colon cell xenograft model and the tissue distribution of xanthenes and their phase II metabolites. *Mol. Nutr. Food Res.* **2013**, *57*, 203–211. [\[CrossRef\]](#)
13. Bissoli, I.; Muscari, C. Doxorubicin and α -Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids. *Biomed. Pharmacother.* **2020**, *124*, 109927. [\[CrossRef\]](#)
14. Adli, A.D.F.; Jahanban-Esfahlan, R.; Seidi, K.; Samandari-Rad, S.; Zarghami, N. An overview on Vadimezan (DMXAA): The vascular disrupting agent. *Chem. Biol. Drug Des.* **2018**, *91*, 996–1006. [\[CrossRef\]](#)
15. Baguley, B.C.; McKeage, M.J. ASA404: A tumor vascular-disrupting agent with broad potential for cancer therapy. *Future Oncol.* **2010**, *6*, 1537–1543. [\[CrossRef\]](#)
16. Le Naour, J.; Zitvogel, L.; Galluzzi, L.; Vacchelli, E.; Kroemer, G. Trial watch: STING agonists in cancer therapy. *Oncot Immunology* **2020**, *9*, 1777624. [\[CrossRef\]](#)
17. Shih, A.Y.; Damm-Ganamet, K.L.; Mirzadegan, T. Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA. *Biophys. J.* **2018**, *114*, 32–39. [\[CrossRef\]](#)
18. Liu, W.; Kim, G.B.; Krump, N.A.; Zhou, Y.; Riley, J.L.; You, J. Selective reactivation of STING signaling to target Merkel cell carcinoma. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 13730–13739. [\[CrossRef\]](#)

19. Chen, D.; Yu, Q.; Huang, X.; Dai, H.; Luo, T.; Shao, J.; Chen, J.; Huang, W.; Dong, X. A Highly-Efficient Type I Photosensitizer with Robust Vascular-Disruption Activity for Hypoxic-and-Metastatic Tumor Specific Photodynamic Therapy. *Small* **2020**, *16*, e2001059. [\[CrossRef\]](#)
20. Patra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; del Pilar Rodriguez-Torres, M.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. *J. Nanobiotechnol.* **2018**, *16*, 71. [\[CrossRef\]](#)
21. Ambekar, R.S.; Choudhary, M.; Kandasubramanian, B. Recent advances in dendrimer-based nanoplatform for cancer treatment: A review. *Eur. Polym. J.* **2020**, *126*, 109546. [\[CrossRef\]](#)
22. Tunki, L.; Kulhari, H.; Sistla, R.; Pooja, D. 5—Dendrimer-Based Targeted Drug Delivery. In *Pharmaceutical Applications of Dendrimers*; Chauhan, A., Kulhari, H., Eds.; Micro and Nano Technologies; Elsevier: Amsterdam, The Netherlands, 2020; pp. 107–129. ISBN 978-0-12-814527-2.
23. Mahesh, S.; Tang, K.-C.; Raj, M. Amide Bond Activation of Biological Molecules. *Molecules* **2018**, *23*, 2615. [\[CrossRef\]](#)
24. Luo, G.-F.; Chen, W.-H.; Liu, Y.; Lei, Q.; Zhuo, R.-X.; Zhang, X.-Z. Multifunctional Enveloped Mesoporous Silica Nanoparticles for Subcellular Co-delivery of Drug and Therapeutic Peptide. *Sci. Rep.* **2014**, *4*, 6064. [\[CrossRef\]](#)
25. Bradshaw, P.R.; Wilson, I.D.; Gill, R.U.; Butler, P.J.; Dilworth, C.; Athersuch, T.J. Metabolic Hydrolysis of Aromatic Amides in Selected Rat, Minipig, and Human In Vitro Systems. *Sci. Rep.* **2018**, *8*, 2405. [\[CrossRef\]](#)
26. Kumari, R.; Majumder, M.M.; Lievonen, J.; Silvennoinen, R.; Anttila, P.; Nupponen, N.N.; Lehmann, F.; Heckman, C.A. Prognostic significance of esterase gene expression in multiple myeloma. *Br. J. Cancer* **2021**, *124*, 1428–1436. [\[CrossRef\]](#)
27. Dong, H.; Pang, L.; Cong, H.; Shen, Y.; Yu, B. Application and design of esterase-responsive nanoparticles for cancer therapy. *Drug Deliv.* **2019**, *26*, 416–432. [\[CrossRef\]](#)
28. Kurtoglu, Y.E.; Mishra, M.K.; Kannan, S.; Kannan, R.M. Drug release characteristics of PAMAM dendrimer–drug conjugates with different linkers. *Int. J. Pharm.* **2010**, *384*, 189–194. [\[CrossRef\]](#)
29. Markowicz, J.; Uram, Ł.; Wołowicz, S.; Rode, W. Biotin Transport-Targeting Polysaccharide-Modified PAMAM G3 Dendrimer as System Delivering α -Mangostin into Cancer Cells and *C. elegans* Worms. *Int. J. Mol. Sci.* **2021**, *22*, 12925. [\[CrossRef\]](#)
30. Perumal, D.; Golla, M.; Pillai, K.S.; Raj, G.; Krishna, P.K.A.; Varghese, R. Biotin-decorated NIR-absorbing nanosheets for targeted photodynamic cancer therapy. *Org. Biomol. Chem.* **2021**, *19*, 2804–2810. [\[CrossRef\]](#)
31. Uram, Ł.; Szuster, M.; Filipowicz, A.; Zareba, M.; Wałajtyś-Rode, E.; Wołowicz, S. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3 dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs. *Bioorg. Med. Chem.* **2017**, *25*, 706–713. [\[CrossRef\]](#)
32. Yang, W.; Cheng, Y.; Xu, T.; Wang, X.; Wen, L.-P. Targeting cancer cells with biotin–dendrimer conjugates. *Eur. J. Med. Chem.* **2009**, *44*, 862–868. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Yellepeddi, V.; Kumar, A.; Palakurthi, S. Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. *Anticancer Res.* **2009**, *29*, 2933–2943. [\[PubMed\]](#)
34. Ma, J.; Yao, H. Dendrimer-paclitaxel complexes for efficient treatment in ovarian cancer: Study on OVCAR-3 and HEK293T cells. *Acta Biochim. Pol.* **2018**, *65*, 219–225. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Hemmer, R.; Hall, A.; Spaulding, R.; Rossow, B.; Hester, M.; Caroway, M.; Haskamp, A.; Wall, S.; Bullen, H.A.; Morris, C.; et al. Analysis of Biotinylated Generation 4 Poly(amidoamine) (PAMAM) Dendrimer Distribution in the Rat Brain and Toxicity in a Cellular Model of the Blood-Brain Barrier. *Molecules* **2013**, *18*, 11537–11552. [\[CrossRef\]](#)
36. Smith, P.E.S.; Brender, J.R.; Dürr, U.H.N.; Xu, J.; Mullen, D.G.; Holl, M.M.B.; Ramamoorthy, A. Solid-State NMR Reveals the Hydrophobic-Core Location of Poly(amidoamine) Dendrimers in Biomembranes. *J. Am. Chem. Soc.* **2010**, *132*, 8087–8097. [\[CrossRef\]](#)
37. Honnen, S. *Caenorhabditis elegans* as a powerful alternative model organism to promote research in genetic toxicology and biomedicine. *Arch. Toxicol.* **2017**, *91*, 2029–2044. [\[CrossRef\]](#)
38. Tomalia, D.A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A New Class of Polymers: Starburst-Dendritic Macromolecules. *Polym. J.* **1985**, *17*, 117–132. [\[CrossRef\]](#)
39. Czarnik-Kwaśniak, J.; Kwaśniak, K.; Tutaj, K.; Filiński, I.; Uram, Ł.; Stompor, M.; Wołowicz, S. Glucoheptoamidated polyamidoamine PAMAM G3 dendrimer as a vehicle for succinate linked doxorubicin; enhanced toxicity of DOX against grade IV glioblastoma U-118 MG cells. *J. Drug Deliv. Sci. Technol.* **2020**, *55*, 101424. [\[CrossRef\]](#)
40. Stiernagle, T. Maintenance of *C. elegans*. In *WormBook*; The *C. elegans* Research Community, Ed.; WormBook: Pasadena, CA, USA, 2006. [\[CrossRef\]](#)
41. Crosignani, S.; Gonzalez, A.J.; Swinnen, D. Polymer-Supported Mukaiyama Reagent: A Useful Coupling Reagent for the Synthesis of Esters and Amides. *Org. Lett.* **2004**, *6*, 4579–4582. [\[CrossRef\]](#)
42. Czerniecka-Kubicka, A.; Tutka, P.; Pyda, M.; Walczak, M.; Uram, Ł.; Misiorek, M.; Chmiel, E.; Wołowicz, S. Stepwise Glucoheptoamidation of Poly(Amidoamine) Dendrimer G3 to Tune Physicochemical Properties of the Potential Drug Carrier: In Vitro Tests for Cytisine Conjugates. *Pharmaceutics* **2020**, *12*, 473. [\[CrossRef\]](#)
43. Martinho, N.; Florindo, H.; Silva, L.; Brocchini, S.; Zloh, M.; Barata, T. Molecular Modeling to Study Dendrimers for Biomedical Applications. *Molecules* **2014**, *19*, 20424–20467. [\[CrossRef\]](#)
44. Zhang, S.-J.; Ding, Z.-S.; Jiang, F.-S.; Ge, Q.-F.; Guo, D.-W.; Li, H.-B.; Hu, W.-X. Synthesis, anticancer evaluation and docking study of vadimezan derivatives with carboxyl substitution. *MedChemComm* **2014**, *5*, 512–520. [\[CrossRef\]](#)

45. Lv, S.; Tang, Z.; Song, W.; Zhang, D.; Li, M.; Liu, H.; Cheng, J.; Zhong, W.; Chen, X. Inhibiting Solid Tumor Growth In Vivo by Non-Tumor-Penetrating Nanomedicine. *Small* **2017**, *13*, 1600954. [CrossRef]
46. AAT Bioquest. Available online: <https://www.aatbio.com/tools/ic50-calculator> (accessed on 6 January 2022).
47. Kurniawan, Y.S.; Priyanga, K.T.A.; Jumina; Pranowo, H.D.; Sholikhah, E.N.; Zulkarnain, A.K.; Fatimi, H.A.; Julianus, J. An Update on the Anticancer Activity of Xanthone Derivatives: A Review. *Pharmaceutics* **2021**, *14*, 1144. [CrossRef]
48. Castanheiro, R.A.P.; Silva, A.M.S.; Campos, N.A.N.; Nascimento, M.S.J.; Pinto, M.M.M. Antitumor Activity of Some Prenylated Xanthenes. *Pharmaceutics* **2009**, *2*, 33–43. [CrossRef]
49. Teh, S.S.; Ee, G.C.L.; Mah, S.H.; Lim, Y.M.; Ahmad, Z. Cytotoxicity and Structure-Activity Relationships of Xanthone Derivatives from *Mesua beccariana*, *Mesua ferrea* and *Mesua congestiflora* towards Nine Human Cancer Cell Lines. *Molecules* **2013**, *18*, 1985–1994. [CrossRef]
50. Singh, J.; Jain, K.; Mehra, N.K.; Jain, N.K. Dendrimers in anticancer drug delivery: Mechanism of interaction of drug and dendrimers. *Artif. Cells Nanomed. Biotechnol.* **2016**, *44*, 1626–1634. [CrossRef]
51. Zeng, Y.; Kurokawa, Y.; Win-Shwe, T.-T.; Zeng, Q.; Hirano, S.; Zhang, Z.; Sone, H. Effects of PAMAM dendrimers with various surface functional groups and multiple generations on cytotoxicity and neuronal differentiation using human neural progenitor cells. *J. Toxicol. Sci.* **2016**, *41*, 351–370. [CrossRef]
52. Janaszewska, A.; Lazniewska, J.; Trzepiński, P.; Marcinkowska, M.; Klajnert-Maculewicz, B. Cytotoxicity of Dendrimers. *Biomolecules* **2019**, *9*, 330. [CrossRef]
53. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A.K.; Thomas, T.P.; Mulé, J.; Baker, J.R., Jr. Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor. *Pharm. Res.* **2002**, *19*, 1310–1316. [CrossRef]
54. Thomas, T.P.; Majoros, I.J.; Kotlyar, A.; Kukowska-Latallo, J.F.; Bielinska, A.; Myc, A.A.; Baker, J.J.R. Targeting and Inhibition of Cell Growth by an Engineered Dendritic Nanodevice. *J. Med. Chem.* **2005**, *48*, 3729–3735. [CrossRef]
55. de Almeida, M.S.; Susnik, E.; Drasler, B.; Taladriz-Blanco, P.; Petri-Fink, A.; Rothen-Rutishauser, B. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. *Chem. Soc. Rev.* **2021**, *50*, 5397–5434. [CrossRef]
56. Adli, A.D.F.; Jahanban-Esfahlan, R.; Seidi, K.; Farajzadeh, D.; Behzadi, R.; Zarghami, N. Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice. *Adv. Pharm. Bull.* **2021**, *11*, 385–392. [CrossRef]
57. van Dongen, M.A.; Vaidyanathan, S.; Holl, M.M.B. PAMAM dendrimers as quantized building blocks for novel nanostructures. *Soft Matter* **2013**, *9*, 11188–11196. [CrossRef]
58. Uram, Ł.; Szuster, M.; Misiorek, M.; Filipowicz, A.; Wołowicz, S.; Wałajtys-Rode, E. The effect of G3 PAMAM dendrimer conjugated with B-group vitamins on cell morphology, motility and ATP level in normal and cancer cells. *Eur. J. Pharm. Sci.* **2017**, *102*, 275–283. [CrossRef]
59. Kurose, H.; Shibata, M.-A.; Iinuma, M.; Otsuki, Y. Alterations in Cell Cycle and Induction of Apoptotic Cell Death in Breast Cancer Cells Treated with α -Mangostin Extracted from Mangosteen Pericarp. *J. Biomed. Biotechnol.* **2012**, *2012*, 672428. [CrossRef]
60. Kwak, H.-H.; Kim, I.-R.; Kim, H.-J.; Park, B.-S.; Yu, S.-B. α -Mangostin Induces Apoptosis and Cell Cycle Arrest in Oral Squamous Cell Carcinoma Cell. *Evid.-Based Complement. Altern. Med.* **2016**, *2016*, 5352412. [CrossRef]
61. Lucio, D.; Martínez-Ohárriz, M.C.; Gu, Z.; He, Y.; Aranaz, P.; Vizmanos, J.L.; Irache, J.M. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using *C. elegans*. *Int. J. Pharm.* **2018**, *547*, 97–105. [CrossRef]
62. Martínez-López, A.L.; González-Navarro, C.J.; Aranaz, P.; Vizmanos, J.L.; Irache, J.M. In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using *Caenorhabditis elegans* as a model under hyperglycemic conditions. *Acta Pharm. Sin. B* **2021**, *11*, 989–1002. [CrossRef]
63. Ma, H.; Bertsch, P.M.; Glenn, T.C.; Kabengi, N.; Williams, P.L. Toxicity of manufactured zinc oxide nanoparticles in the nematode *Caenorhabditis elegans*. *Environ. Toxicol. Chem.* **2009**, *28*, 1324–1330. [CrossRef]
64. Marcelino, M.Y.; Borges, F.A.; Scorzoni, L.; Singulani, J.D.L.; Garms, B.C.; Niemeyer, J.C.; Guerra, N.B.; Brasil, G.S.P.; Mussagy, C.U.; Carvalho, F.A.D.O.; et al. Synthesis and characterization of gold nanoparticles and their toxicity in alternative methods to the use of mammals. *J. Environ. Chem. Eng.* **2021**, *9*, 106779. [CrossRef]